附属病院 とちぎ子ども医療センター

熊谷 秀規

クマガイ ヒデキ  (Hideki KUMAGAI)

基本情報

所属
自治医科大学 医学部小児科学講座 /附属病院とちぎ子ども医療センター小児科 教授
学位
博士(医学)(2001年12月 岩手医科大学)

J-GLOBAL ID
200901088615999604
researchmap会員ID
5000060482

学歴

 1

論文

 104
  • Yuri Matsubara, Yosikazu Nakamura, Yoshiko Nakayama, Tomonori Yano, Hideki Ishikawa, Hideki Kumagai, Junji Umeno, Keiichi Uchida, Keisuke Jimbo, Toshiki Yamamoto, Hideyuki Ishida, Okihide Suzuki, Koichi Okamoto, Fumihiko Kakuta, Yuhki Koike, Yuko Kawasaki, Hirotsugu Sakamoto
    Journal of gastroenterology and hepatology 2024年12月2日  
    BACKGROUND AND AIM: Peutz-Jeghers syndrome (PJS) and juvenile polyposis syndrome (JPS) are autosomal dominant diseases associated with high cancer risk. In Japan, knowledge about the prevalence and incidence of PJS and JPS is lacking despite being crucial for providing appropriate medical support. We aimed to determine the prevalence and incidence of these diseases. METHODS: In 2022, a nationwide questionnaire survey was conducted to determine the number of patients with PJS or JPS by sex and the number of newly confirmed cases from 2019 to 2021. The target facilities included gastroenterology, pediatrics, and pediatric surgery departments, which were stratified into seven classes on the basis of the total number of beds. We randomly selected target facilities using different extraction rates in each class, resulting in 1748/2912 facilities (extraction rate: 60%) as the final sample. We calculated the estimated number of patients using the response and extraction rates. RESULTS: A total of 1077 facilities responded to the survey. The estimated numbers of patients with PJS and JPS were 701 (95% confidence interval [CI]: 581-820) and 188 (95% CI: 147-230), respectively. The 3-year period prevalences of PJS and JPS were 0.6/100000 and 0.15/100000, whereas the incidences in 2021 were 0.07/100000 and 0.02/100000, respectively. Male patients constituted 53.5% and 59.6% in the PJS and JPS groups, respectively. CONCLUSIONS: We determined the prevalence and incidence of PJS and JPS in Japan for the first time. Further research is needed to obtain more detailed information, including the clinical differences and outcomes in Japan.
  • Ayako Miyazawa, Ryusuke Nambu, Hirotaka Shimizu, Takahiro Kudo, Takuya Nishizawa, Hideki Kumagai, Shin-Ichiro Hagiwara, Emiri Kaji, Tatsuki Mizuochi, Shingo Kurasawa, Fumihiko Kakuta, Takashi Ishige, Toshiaki Shimizu, Itaru Iwama, Katsuhiro Arai
    Inflammatory bowel diseases 2024年11月19日  
    BACKGROUND: Although ulcerative proctitis (UP) in children is considered relatively mild, some patients have proximal disease extension and require immunosuppressive treatment. We investigated clinical characteristics and course of refractory UP in a multicenter pediatric cohort. METHODS: Analyzing data obtained between 2013 and 2022 at 10 institutions specializing in pediatric inflammatory bowel disease, we elucidated natural history and factors predicting a need for immunosuppressive UP treatment. We compared patients given immunosuppressants and/or biologic agents (immunosuppressive treatment group) with those given 5-aminosalicylic acid (5-ASA) alone (5-ASA group). RESULTS: Fifty-five patients were followed for 3.5 years. The median Pediatric Ulcerative Colitis Activity Index at diagnosis was 20. The commonest treatment, 5-ASA suppository monotherapy in 40% of patients, showed the worst compliance. Clinical remission was achieved at least once in 95% of all patients. Disease extension beyond the splenic flexure occurred in 51%. Immunosuppressive treatment was given to 37%; biologic agents were used for 18%. Rates of endoscopically demonstrated inflammation, including Ra/Rs at diagnosis and extension beyond the left-sided colon, were higher in the immunosuppressive treatment group (70% vs 38%, P < 0.05; 95% vs 27%, P < 0.0001). The log-rank test and multivariate Cox proportional hazards regression showed that time to first clinical remission exceeding 3 months predicted the need for biologics. CONCLUSION: The typical initial treatment of pediatric UP was 5-ASA suppositories, despite poor compliance. Biologics or other immunosuppressive treatments were needed in 37% of patients. Close follow-up with adjustment of treatment should be considered in children with UP as its clinical course varies.
  • Yuko Okada, Atsushi Kanno, Naoki Sano, Yusuke Hashimoto, Koji Yokoyama, Hideki Kumagai, Toshihiro Tajima
    Pediatrics International 2024年1月  
  • Ryusuke Nambu, Takahiro Kudo, Nao Tachibana, Hirotaka Shimizu, Tatsuki Mizuochi, Sawako Kato, Mikihiro Inoue, Hideki Kumagai, Takashi Ishige, Reiko Kunisaki, Atsuko Noguchi, Toshifumi Yodoshi, Shin-Ichiro Hagiwara, Shigeo Nishimata, Fumihiko Kakuta, Takeshi Saito, Itaru Iwama, Yuri Hirano, Toshiaki Shimizu, Katsuhiro Arai
    Journal of gastroenterology and hepatology 39(2) 312-318 2023年12月6日  
    BACKGROUND AND AIM: Even with increasing numbers of biologic agents available for management of ulcerative colitis (UC), infliximab (IFX) retains an important place in treatment of pediatric patients with this disease. As few reports have addressed outcomes in pediatric UC patients who had to discontinue IFX, we examined clinical course and prognosis after IFX failure in pediatric UC. METHODS: A prospective cohort study of pertinent cases enrolled in the Japanese Pediatric Inflammatory Bowel Disease Registry between 2012 and 2020 was conducted to determine outcomes for pediatric UC patients who received IFX but required its discontinuation during follow-up (IFX failure). RESULTS: Of the 301 pediatric UC patients in the registry, 75 were treated with IFX; in 36 of these, IFX was discontinued during follow-up. Severity of UC at onset and absence of concomitant immunomodulator therapy were significant risk factors for IFX failure (P = 0.005 and P = 0.02, respectively). The cumulative colectomy rate after IFX failure was 41.3% at 1 year and 47.5% at 2 years. Colectomy was significantly more frequent when IFX was discontinued before June 1, 2018, than when IFX was discontinued later (P = 0.013). This difference likely involves availability of additional biologic agents for treatment of UC beginning in mid-2018 (P = 0.005). CONCLUSION: In pediatric UC patients, approximately 50% underwent colectomy during a 2-year interval following IFX failure. Prognosis after IFX failure appeared to improve with availability of new biologic agents and small-molecule drugs in mid-2018.

MISC

 191
  • 熊谷秀規
    小内科 52(増刊号) 547-550 2020年12月  招待有り筆頭著者
  • 山本 博徳, 阿部 孝, 石黒 信吾, 内田 恵一, 川崎 優子, 熊谷 秀規, 斉田 芳久, 佐野 寧, 竹内 洋司, 田近 正洋, 中島 健, 阪埜 浩司, 船坂 陽子, 堀 伸一郎, 山口 達郎, 吉田 輝彦, 坂本 博次, 石川 秀樹, 岩間 毅夫, 岡崎 康司, 斎藤 豊, 松浦 成昭, 武藤 倫弘, 冨田 尚裕, 秋山 卓士, 山本 敏樹, 石田 秀行, 中山 佳子
    遺伝性腫瘍 20(2) 59-78 2020年9月  
    Peutz-Jeghers症候群は,食道を除く全消化管の過誤腫性ポリポーシスと皮膚・粘膜の色素斑を特徴とする希少疾患である.STK11遺伝子の生殖細胞系列の病的バリアントを原因とし,常染色体優性遺伝形式をとる.また,がん遺伝子パネル検査によって診断される可能性がある.本症候群でみられる過誤腫性ポリープは小腸に好発し,ポリープが大きくなると出血,腸閉塞,腸重積の原因となる.初回の消化管サーベイランスは症状がなくても8歳頃を目安に行い,10〜15mm以上の小腸ポリープは内視鏡的ポリープ切除術を行う.消化管,乳房,膵,子宮,卵巣,肺,精巣などに悪性腫瘍の発生が認められ,適切なサーベイランスが必要である.本診療ガイドラインでは,小児から成人にかけてシームレスに,正確な診断と適切な治療・サーベイランスが行われるよう,基本的事項を解説し,4個のクリニカルクエスチョンと推奨を作成した.(著者抄録)
  • 高山 哲治, 五十嵐 正広, 大住 省三, 岡 志郎, 角田 文彦, 久保 宜明, 熊谷 秀規, 佐々木 美香, 菅井 有, 菅野 康吉, 武田 祐子, 土山 寿志, 阪埜 浩司, 深堀 優, 古川 洋一, 堀松 高博, 六車 直樹, 石川 秀樹, 岩間 毅夫, 岡崎 康司, 斎藤 豊, 松浦 成昭, 武藤 倫弘, 冨田 尚裕, 秋山 卓士, 山本 敏樹, 石田 秀行, 中山 佳子
    遺伝性腫瘍 20(2) 93-114 2020年9月  
    Cowden症候群/PTEN過誤腫症候群は,PTEN遺伝子の生殖細胞系列の病的バリアントを原因とする常染色体優性遺伝性の希少疾患である.消化管,皮膚,粘膜,乳房,甲状腺,子宮内膜,脳などに過誤腫性病変の多発を特徴とする.巨頭症および20歳代後半までに多発性皮膚粘膜病変を発症することが多い.ときに小児期に多発する消化管病変,自閉スペクトラム症,知的障害が診断の契機となる.また,がん遺伝子パネル検査によって診断される可能性がある.乳癌,甲状腺癌,子宮内膜癌,大腸癌,腎細胞癌などの悪性腫瘍を合併するリスクが高く,適切なサーベイランスが必要である.本診療ガイドラインでは,小児から成人にかけてシームレスに,正確な診断と適切な治療・サーベイランスが行われるよう,基本的事項を解説し,4個のクリニカルクエスチョンと推奨を作成した.(著者抄録)
  • 虻川大樹, 新井勝大, 青松友槻, 石毛 崇, 井上幹大, 岩間 達, 内田恵一, 工藤孝広, 国崎玲子, 熊谷秀規, 齋藤 武, 清水泰岳, 神保圭祐, 高橋美智子, 立花奈緒, 南部隆亮, 福岡智哉, 水落建輝, 清水俊明, 田尻 仁
    日本小児科学会雑誌 124(8) 1199-1199 2020年8月  
  • 福井 慶介, 齋藤 傑, 森川 康英, 小倉 一輝, 井上 俊, 小太刀 豪, 俣野 美雪, 門田 行史, 高橋 和郎, 郡司 勇治, 沼崎 啓, 渕本 康史, 横山 孝二, 熊谷 秀規
    日本小児科学会雑誌 124(5) 876-876 2020年5月  

書籍等出版物

 11

共同研究・競争的資金等の研究課題

 25

産業財産権

 1

学術貢献活動

 2

メディア報道

 4